Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.
Leuk Lymphoma. 2023 Dec;64(14):2324-2326. doi: 10.1080/10428194.2023.2255804. Epub 2023 Sep 10.
The outcome of chronic myeloid leukemia (CML) patients improved in the last decade. Clinical prognostic scoring systems aim to provide information about survival in the long-term, without determining from baseline the subset of patients who require a strictly monitoring because at increased risk of failure. Imatinib, the first-generation tyrosine kinase inhibitor (TKI), is still widely used as frontline treatment: recently, the imatinib therapy failure (IMTF) score was proposed to identify the failure free survival. Aim of our study was to validate this index in a large cohort of patients treated with imatinib.
在过去的十年中，慢性髓性白血病（CML）患者的治疗效果得到了改善。临床预后评分系统旨在提供长期生存信息，而不是从基线确定需要严格监测的患者亚组，因为这些患者的失败风险增加。伊马替尼是第一代酪氨酸激酶抑制剂（TKI），仍广泛用于一线治疗：最近，提出了伊马替尼治疗失败（IMTF）评分来识别无失败生存。我们的研究目的是在接受伊马替尼治疗的大量患者中验证该指标。
